FIELD: medicine.
SUBSTANCE: claimed invention deals with soluble isoforms of neuregulin-1, which represent post-translation modifications. Claimed is application of neuregulin-1 β for production of medicine for treatment of neurological diseases (version - for enhancement of memory and cognition), where isoform of neuregulin-1 β represents part of extracellular domain of neuregulin-1 β, where said part has molecular weight 25-32 kDa and isoelectric point (pl) in range from 5 to 9.5 and versions of respective treatment methods. Claimed is pharmaceutical composition for treatment of neurological diseases, which includes recombinant soluble isoform of neuregulin-1 β, where neuregulin-1 β isoform represents part of extracellular domain of neuregulin-1 β, where said part has molecular weight 25-32 kDa and pl in range from 5 to 9.5 and additional medication for treatment of neurological diseases. It can be applied as medication in case of cognitive neurological diseases, in particular schizophrenia, Alzheimer's and Parkinson's disease.
EFFECT: clear and beneficial neuro-protective effect of claimed recombinant soluble isoform of neuregulin-1β is demonstrated, with no negative effects observed, unlike control neuroleptics.
14 cl, 12 dwg
